COVID-19 Continues to Impact Clinical Research, says GlobalData

Gastrointestinal studies currently have the highest proportion of disrupted clinical trials due to COVID-19. GlobalData found that 2.04% of gastrointestinal clinical trials were disrupted due to COVID-19, followed by hematological disorders at 2%.

Infectious disease clinical trials have the lowest proportion of disrupted trials, with just 0.91% of trials disrupted and the lowest proportion of Phase I and Phase II disruptions among the top ten therapy areas.

While oncology studies have the highest number of disrupted trials among the top ten therapeutic areas, these studies also have the second lowest proportion of trial disruptions due to COVID-19 (1.18%). Teams conducting oncology studies have demonstrated capability in preventing disturbances to late-phase studies and hold the lowest proportion of Phase III (0.33%) and Phase IV (0.09%) disruptions.